Tailoring LDL-C-Lowering Therapy to Patient Cardiovascular Risk: Identifying Effective Strategies for Patients with Diabetes
Nov 30, 2019
Reducing LDL-C and Cardiovascular Risk with Nonstatin Therapy: From Evidence to Practice
Jul 02, 2019
Managing LDL-C to Reduce Cardiovascular Disease Risk: Defining Best Clinical Practice
Apr 22, 2019
Diabetes Therapies Exploring Mechanisms and Role of the Cardiovascular Clinician in CVD Risk Management
Mar 24, 2019
The Perfect Storm of Heart Failure and Diabetes: Insights into Pathophysiology and Evidence-Based Treatment Strategies
Nov 08, 2016
New Pathways to GLYCEMIC CONTROL: Focus on the Kidney
Oct 28, 2014
November 30, 2019
In this program, a panel of experts will discuss the latest guidelines for managing LDL-C in patients with diabetes, interpret data with nonstatin, LDL-C-lowering therapies, describe improving access to PCSK9 inhibitors and tips for achieving earlier access,
July 02, 2019
In this symposium, lipid experts Dr. Robert Giugliano, Dr. Marc Sabatine, and Dr. James Underberg will describe best practices for internists in managing LDL-C and reducing the risk for major cardiovascular events with the addition of nonstatin therapy.
April 22, 2019
In this program, an expert faculty will discuss the evidence and recommendations for managing LDL-C in patients with ASCVD, familial hypercholesterolemia (FH), diabetes, and those at increased cardiovascular risk without ASCVD.
March 24, 2019
November 08, 2016
In this educational initiative, experts will address the needs of cardiologists for 1) a grasp of the relationship between DM and HF and the pathophysiology of HF in DM, 2) an explanation of clinical evidence for HF drugs in patients with DM, and 3) an assessment of the profiles of traditional and newer antidiabetic agents in patients with/at risk for cardiovascular disease and interpretation of heart failure-related outcomes.
No Credit Available
October 28, 2014
Presentations by Jay Shubrook, DO (Chair), Eugene Cersosimo, MD, PhD, and Robert Henry, MD. discussing the role of glucose regulation and SGLT 2 inhibitors in antihyperglycemic therapy